Bone Marrow Transplantation Unit, Hospital Italiano de La Plata, La Plata, Argentina.
Leuk Lymphoma. 2009 Dec;50 Suppl 2:9-15. doi: 10.3109/10428190903370395.
The presence of the Philadelphia chromosome is a poor prognosis factor in acute lymphoblastic leukemia (ALL), in both children and adults. Using molecular techniques of the gen bcr/abl, it is possible to detect the abnormality, in up to the 40% of adult patients. The unsatisfactory results with conventional chemotherapy schemes have determined the intensification of the treatments and the consideration of allogenic bone marrow transplants as the best therapeutic instance. The development of tyrosine kinase inhibitors have become a therapeutic improvement in the treatment of Philadelphia chromosome-positive ALL, being combined with chemotherapy schemes, only in a selected group of patients, even in therapeutic programs that include transplant.
费城染色体的存在是儿童和成人急性淋巴细胞白血病（ALL）预后不良的一个因素。通过基因 bcr/abl 的分子技术，可以检测到高达 40%的成年患者的异常。传统化疗方案的不理想结果决定了治疗的强化，以及同种异体骨髓移植作为最佳治疗方法的考虑。酪氨酸激酶抑制剂的发展已成为治疗费城染色体阳性 ALL 的一种治疗进展，仅在选定的患者群体中与化疗方案联合使用，即使在包括移植的治疗方案中也是如此。
